NRX Pharmaceuticals (NRXP) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($141.3 million vs $125.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXP | RNA |
|---|---|---|
| Share price | $2.89 | $8.26 |
| Market cap | $125.12M | $141.29M |
| 1-day change | -0.34% | +4.16% |
| YTD return | +6.64% | — |
| 1-year return | -19.27% | — |
| 5-year return | -97.18% | — |
| EPS (TTM) | $-0.58 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.06 | $16.77 |
| 52-week low | $1.62 | $7.63 |
| Distance from 52-week high | -42.83% | -50.75% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1232.18% | +202.66% |
| Average volume | 865.49K | 259.35K |
| Shares outstanding | 43.30M | 17.11M |
| Employees | 29 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
NRXP vs RNA FAQ
Which is bigger, NRX Pharmaceuticals or Atrium Therapeutics?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $141.29M compared with $125.12M for NRX Pharmaceuticals (NRXP).
Are NRX Pharmaceuticals and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.